Companies developing cell therapies, as well as the investors giving them money, have been focusing on ways to deliver the drugs in an outpatient setting as a way to get around bundled payments. However, outpatient use remains challenging due to the need to monitor patients and some cell therapies could yield better outcomes in inpatient settings.
The issue has come up over the years as the first wave of chimeric antigen receptor T-cell therapies required extensive monitoring and were reimbursed as inpatient therapies, reimbursed with a bundled payment by Medicare
